Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group Paola PeregoGeorg HempelOn behalf of the EORTC PAMM Group Review Article 28 December 2017 Pages: 427 - 441
First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice? Shuyun WangAiqin GaoYuping Sun Review Article 11 January 2018 Pages: 443 - 453
Pharmacokinetics of dacarbazine (DTIC) in pregnancy Ira Kantrowitz-GordonKaren HaysMary F. Hebert Original Article 05 January 2018 Pages: 455 - 460
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202) Hiroaki YanagimotoHideyoshi ToyokawaTatsuya Ioka Original Article 05 January 2018 Pages: 461 - 468
Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma Jingnan WangZhirong ZhangJie He Original Article 08 January 2018 Pages: 469 - 481
Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations Nilsa Rivera-Del ValleTiewei ChengJoya Chandra Original Article 08 January 2018 Pages: 483 - 495
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer Kathleen MooreZhi-Yi ZhangVikram Kansra Original Article Open access 10 January 2018 Pages: 497 - 503
A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab Francisco J. EstevaJustin StebbingSang Joon Lee Original Article Open access 12 January 2018 Pages: 505 - 514
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach Myrna CandelariaDerlis GonzalezSusana Millán Original Article Open access 24 January 2018 Pages: 515 - 527
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors John NemunaitisAnnie YoungAlbiruni Razak Original Article 24 January 2018 Pages: 529 - 537
Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study Hiroyuki OhnumaYasushi SatoJunji Kato Original Article 30 January 2018 Pages: 539 - 548
Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma Souichi YanamotoMasahiro UmedaIwai Tohnai Original Article 30 January 2018 Pages: 549 - 554
2-Deoxy-d-glucose enhances TRAIL-induced apoptosis in human gastric cancer cells through downregulating JNK-mediated cytoprotective autophagy Yuting XuQingling WangMaojin Zheng Original Article 31 January 2018 Pages: 555 - 564
Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer Tetsuhiko TairaKiyotaka YohKoichi Goto Original Article 31 January 2018 Pages: 565 - 572
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma Stine Braendegaard WintherJon Kroll BjerregaardPer Pfeiffer Original Article 31 January 2018 Pages: 573 - 578
Role of TPMT and ITPA variants in mercaptopurine disposition Tina GerbekMaria EbbesenKjeld Schmiegelow Original Article 01 February 2018 Pages: 579 - 586
A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies John F. DeekenHongkun WangMichael J. Pishvaian Original Article 01 February 2018 Pages: 587 - 596
Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML Steven BlotnerLin-Chi ChenJianguo Zhi Original Article 01 February 2018 Pages: 597 - 607
A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer Jacob E. ShabasonJerry ChenEdgar Ben-Josef Clinical Trial Report 23 January 2018 Pages: 609 - 614
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs Jessica CusatoLucio BoglioneAntonio D’Avolio Short Communication 22 January 2018 Pages: 615 - 620
A note on improved statistical approaches to account for pseudoprogression Nacer AbroukBryan OronskyDonna Peehl Short Communication 05 February 2018 Pages: 621 - 626
Retraction Note to: Quinoxaline 1,4-dioxides induce G2/M cell cycle arrest and apoptosis in human colon cancer cells Hala U. Gali-MuhtasibMona Diab-AssafMakhluf J. Haddadin Retraction Note 08 January 2018 Pages: 627 - 627
